Tenth Circuit Opinion in PCMA v. Mulready
In an unfortunate – and arguably errant – legal development, the United States Tenth Circuit Court of Appeals on Tuesday issued an unfavorable decision.
Pharmacy Organizations Blast Tenth Circuit Decision Invalidating an Oklahoma Law Regulating PBMs Ruling creates a split in the federal courts that could lead to the Supreme Court
Ruling creates a split in the federal courts that could lead to the Supreme Court.
NACDS Applauds Sen. Crapo’s Bipartisan Approach to Reducing Patients’ Drug Costs and Protecting Their Freedom of Pharmacy Leadership role on a key committee helps to confront “pharmaceutical benefit manipulation” by “PBM” middlemen
Sen. Crapo is leading a press conference in Twin Falls, ID, on addressing PBM practices that have grown increasingly complex and opaque in recent years at the expense of patients and taxpayers.
NACDS Lauds Senate Finance Committee for Bipartisan Efforts to Deliver Real and Comprehensive PBM Reform that is Meaningful for Patients and Pharmacies Looks forward to continuing work with leaders in the U.S. Congress to address the “pharmaceutical benefit manipulation” that harms the most vulnerable in the Medicaid and Medicare programs
NACDS looks forward to continuing work with leaders in the U.S. Congress to address the “pharmaceutical benefit manipulation” that harms the most vulnerable in the Medicaid and Medicare programs.
NACDS to the U.S. Congress: Real PBM Reform Must Include Medicare and Medicaid A newly released NACDS video urges this message ahead of a July 26 legislative markup scheduled by the U.S. Senate Committee on Finance
A newly released NACDS video urges this message ahead of a July 26 legislative markup scheduled by the U.S. Senate Committee on Finance.
In Case You Missed It: FTC to PBMs: That Was Then; This is Now
The FTC on Thursday voted, 3-0, “to issue a statement cautioning against reliance on prior advocacy statements and studies related to pharmacy benefit managers (PBM) that no longer reflect current market realities.”
In Case You Missed It: Federal Trade Commission Will Vote on Clarifying That Prior Statements and Studies on PBMs “No Longer Reflect Current Market Realities” FTC: “The statement is a response to PBMs' continued reliance on older FTC advocacy materials”
FTC: “The statement is a response to PBMs' continued reliance on older FTC advocacy materials”
NACDS Commends Senate Finance Committee for Scheduling PBM Reform Bill Markup, Pledges Engagement for Real PBM Reform That Addresses Needs of Medicare and Medicaid Patients and Their Pharmacies “S. 1038 and S. 2052 are vital for real PBM reform, and for addressing ‘pharmaceutical benefit manipulation’ that harms the most vulnerable in the Medicaid and Medicare programs.”
“S. 1038 and S. 2052 are vital for real PBM reform, and for addressing ‘pharmaceutical benefit manipulation’ that harms the most vulnerable in the Medicaid and Medicare programs.”
Momentum Builds in Advancement and Coverage of PBM Reform From industry trade press, to publications serving the broader business community, to media outlets relied on by government decision-makers, important story lines about pharmacy benefit manager reform continue to generate headlines and attention across the nation.
From industry trade press, to publications serving the broader business community, to media outlets relied on by government decision-makers, important story lines about pharmacy benefit manager reform continue to generate headlines and attention across the nation.
NACDS Lauds DIR Fee and Pharmacy Access Bill as Vital for PBM Reform Bill aims to preserve seniors’ freedom of pharmacy choice by confronting tactics that bar pharmacies from Part D networks and drive pharmacies out of business
NACDS today praised the bipartisan introduction of the Protect Patient Access to Pharmacies Act (S. 2052) – a bill that would help preserve Medicare beneficiaries’ access to their pharmacy of choice and help stop “pharmaceutical benefit manipulation” that harms patients and pharmacies alike.
